OncoMatch/Clinical Trials/NCT07473167
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Is NCT07473167 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies TC011 for relapsed large b-cell lymphoma.
Treatment: TC011 — This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic chemotherapy
Relapsed/refractory after ≥2 prior lines of systemic chemotherapy
Cannot have received: anti-CD19 agent
Prior therapies such as anti-CD19 agents
Cannot have received: adoptive T-cell therapy
Prior therapies such as ... adoptive T-cell therapy
Cannot have received: gene therapy
Prior therapies such as ... gene therapy
Cannot have received: allogeneic HSCT
Prior therapies such as ... allogeneic HSCT
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Cardiac function
LVEF ≥40%; significant cardiac disease within 6 months [excluded]
Adequate organ, and pulmonary function; LVEF ≥40%; Significant cardiac disease within 6 months [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07473167 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD19 agent, adoptive T-cell therapy, gene therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify